No-deal Brexit stockpiling puts pressure on supply chain

pharmafile | December 17, 2018 | News story | Sales and Marketing brexit, no-deal, pharma, pricing, supply chain 

The stockpiling of medicines in preparation for a no-deal Brexit is putting pressure on the supply chain and causing shortages of generic medicines, according to Simon Dukes, chief executive of the PSNC. The increased demand has in turn led to fluctuating prices, additional costs that will have to be picked up by the NHS.

Speaking to BBC’s 5 Live Breakfast show, Dukes said: “We have supply shortages. They can be for a number of reasons – they can be because of manufacturing problems or transportation issues, or just an increased demand. Where you have those supply shortages, concerns around a ‘no deal’ Brexit are likely to exacerbate those ongoing issues.

“We have worked very closely with the Department of Health and Social Care and fully support what they and the Secretary of State are doing to ensure that all patients get their medicines during the course of the next few months.

“What we are seeing anecdotally is that although the Secretary of State has been very clear and issued a letter to industry that six weeks’ supply should be stockpiled by the manufacturers, what we are seeing is that other stockpiling is happening in other parts of the supply chain, and that may well be exacerbating some of the supply issues.”

The strain on the supply chain has come in response to the government’s request that drugmakers stockpile six weeks’ worth of medicines in preparation for a no-deal crash out of the European Union.

Louis Goss

Related Content


New targeted lung cancer treatment coming to UK under MHRA scheme

The MHRA has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for …


Sickle cell therapy granted innovation passport by MHRA

Bluebird bio has been granted an innovation passport, under the new UK approval process, for …

Biosimilars and Brexit: What’s in store for UK’s biosimilar market?

It’s been 15 years since the first biosimilar entered the market, and the impact of …

Latest content